Table 4:

Linear regression model of change in nodules (Model 1) and % change in IHS4 outcome measure (Model 2) in Adalimumab treated patients in PIONEER 1 and PIONEER 2

Variable	PIONEER 1 Change in Nodules			PIONEER 2 Change in Nodules
Model 1	Estimate	95 % CI	P value	Estimate	95 % CI	P value
Adalimumab	−2.36	(−4.40, −0.31)	0.02	−2.58	(−3.97, −1.19)	<0.001
Hurley Stage 3	2.23	(−0.01, 4.48)	0.05	−0.17	(−1.63, 1.29)	0.82
Family History	−0.74	(−3.19, 1.72)	0.56	−0.59	(−2.17, 0.99)	0.47
Current Smoker	−1.00	(−3.08, 1.08)	0.35	−0.05	(−1.56, 1.46)	0.94
Presence of Draining Tunnels	1.09	(−1.49, 3.66)	0.41	1.87	(0.32, 3.43)	0.02
Antibiotic Use	-	-	-	1.10	(−0.67, 2.88)	0.22
BMI	−0.04	(−0.18, 0.09)	0.54	−0.01	(−0.11, 0.10)	0.89
Male Sex	−0.46	(−2.67, 1.75)	0.68	0.02	(−1.55, 1.60)	0.98
Age	0.03	(−0.06, 0.12)	0.51	0.03	(−0.03, 0.09)	0.38
Variable	PIONEER 1 % Change in IHS4			PIONEER 2 % Change in IHS4
Model 2	Estimate	95 % CI	P value	Estimate	95 % CI	P value
Adalimumab	−18.60	(−33.64, −3.55)	0.02	−39.79	(−54.92, −24.67)	<0.0001
Hurley Stage 3	8.45	(−6.89, 23.80)	0.28	2.54	(−12.83, 17.90)	0.75
Family History	−3.61	(−21.50, 14.28)	0.69	−6.59	(−23.77, 10.59)	0.45
Current Smoker	1.29	(−14.04, 16.63)	0.87	4.68	(−11.71, 21.07)	0.57
Antibiotic Use	-	-	-	16.75	(−2.52, 36.02)	0.09
BMI	0.17	(−0.82, 1.15)	0.74	1.65	(0.50, 2.81)	0.01
Male Sex	10.61	(−5.52, 26.75)	0.20	8.82	(−7.70, 25.34)	0.29
Age	0.27	(−0.40, 0.94)	0.43	−0.04	(−0.72, 0.65)	0.92